HLA-haploidentical hematopoietic SCT from collateral related donors without in vitro T-cell depletion for hematological malignancies

[1]  Yu-Hong Chen,et al.  HLA-mismatched hematopoietic SCT without in vitro T-cell depletion for myelodysplastic syndrome , 2010, Bone Marrow Transplantation.

[2]  Lanping Xu,et al.  Influence of Lymphocyte Recovery on Outcome of Haploidentical Transplantation for Hematologic Malignancies , 2009, Medicine.

[3]  Yu-Hong Chen,et al.  Partially Matched Related Donor Transplantation Can Achieve Outcomes Comparable with Unrelated Donor Transplantation for Patients with Hematologic Malignancies , 2009, Clinical Cancer Research.

[4]  Yu-Hong Chen,et al.  Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[5]  L. Xu,et al.  The impact of graft composition on clinical outcomes in unmanipulated HLA-mismatched/haploidentical hematopoietic SCT , 2009, Bone Marrow Transplantation.

[6]  Q. Jiang,et al.  Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for treatment of hematological malignancies in children. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[7]  Yu-Hong Chen,et al.  HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: Improved outcomes in patients in accelerated phase and blast crisis phase , 2008, Annals of medicine.

[8]  Lanping Xu,et al.  Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation. , 2007, Haematologica.

[9]  K. Sullivan,et al.  Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Wei Han,et al.  Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies , 2006, Bone Marrow Transplantation.

[11]  Yu-Hong Chen,et al.  Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. , 2006, Blood.

[12]  S. Singhal,et al.  Bone marrow transplantation from partially HLA-mismatched family donors for acute leukemia: single-center experience of 201 patients , 2004, Bone Marrow Transplantation.

[13]  Katia Perruccio,et al.  Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants , 2002, Science.

[14]  F. Aversa.  Full haplotype mismatched hematopoietic stem cell transplants. , 2002, Haematologica.

[15]  Philippe Dessen,et al.  Atlas of Genetics and Cytogenetics in Oncology and Haematology, an Interactive Database , 2000, Nucleic Acids Res..

[16]  A. Tosti,et al.  Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. , 1999, Blood.

[17]  M. Martelli,et al.  Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. , 1998, The New England journal of medicine.

[18]  R. Storb,et al.  Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. , 1990, Human immunology.

[19]  K. Sullivan,et al.  Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. , 1989, The New England journal of medicine.

[20]  K. Sullivan,et al.  Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. , 1980, The American journal of medicine.

[21]  R Storb,et al.  Bone-marrow transplantation (second of two parts). , 1975, The New England journal of medicine.